Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important

[Guest guest]

Transplantation. 2007 Sep 15;84(5):650-4.

Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin

plays an important role in the long-term prevention of hepatitis B virus

recurrence.

Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R,

Esteban R.

Hospital General Valle de Hebrón and CIBER EHD, Barcelona, Spain.

mbuti@vhebronnet

Lamivudine combined with hepatitis B immune globulin (HBIg) is the standard of

care for preventing the recurrence hepatitis B virus after liver transplant. To

determine the risk of hepatitis B virus (HBV) recurrence after early withdrawal

of HBIg in patients receiving lamivudine maintenance therapy, 20 patients

receiving a course of HBIg and lamivudine after transplantation and long-term

maintenance therapy with lamivudine and 9 patients receiving HBIg and lamivudine

indefinitely were analyzed. The survival rate was 90% after a mean follow-up of

83 months. The HBV recurrence rate was 14% with a mean period of 91 months free

from HBV recurrence. Both groups had similar HBV recurrence rates, 15% for the

combination and 11% for lamivudine alone. Four patients, 3 of whom were

noncompliant with therapy, experienced posttransplant HBV recurrence. Patients

who adhere to long-term prophylaxis with lamivudine after early withdrawal of

HBIg have a low risk of HBV recurrence, similar to those who receive combination

prophylaxis.

PMID: 17876280 [PubMed - indexed for MEDLINE]

_________________________________________________________________

Climb to the top of the charts!  Play Star Shuffle:  the word scramble challenge

with star power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_oct

[Guest guest]

Transplantation. 2007 Sep 15;84(5):650-4.

Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin

plays an important role in the long-term prevention of hepatitis B virus

recurrence.

Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R,

Esteban R.

Hospital General Valle de Hebrón and CIBER EHD, Barcelona, Spain.

mbuti@vhebronnet

Lamivudine combined with hepatitis B immune globulin (HBIg) is the standard of

care for preventing the recurrence hepatitis B virus after liver transplant. To

determine the risk of hepatitis B virus (HBV) recurrence after early withdrawal

of HBIg in patients receiving lamivudine maintenance therapy, 20 patients

receiving a course of HBIg and lamivudine after transplantation and long-term

maintenance therapy with lamivudine and 9 patients receiving HBIg and lamivudine

indefinitely were analyzed. The survival rate was 90% after a mean follow-up of

83 months. The HBV recurrence rate was 14% with a mean period of 91 months free

from HBV recurrence. Both groups had similar HBV recurrence rates, 15% for the

combination and 11% for lamivudine alone. Four patients, 3 of whom were

noncompliant with therapy, experienced posttransplant HBV recurrence. Patients

who adhere to long-term prophylaxis with lamivudine after early withdrawal of

HBIg have a low risk of HBV recurrence, similar to those who receive combination

prophylaxis.

PMID: 17876280 [PubMed - indexed for MEDLINE]

_________________________________________________________________

Climb to the top of the charts!  Play Star Shuffle:  the word scramble challenge

with star power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_oct